

**Date: 17 June 2025**

To <b>National Stock Exchange of India Limited</b> Exchange Plaza, C-1, Block G, Bandra Kurla Complex, Bandra (E), Mumbai – 400 051 NSE Scrip Symbol: SaiLife	To <b>BSE Limited</b> Phiroze Jeejeebhoy Towers, Dalal Street Mumbai – 400001 BSE Scrip Code: 544306
---	--

**Sub:** Intimation under Regulation 30 of the SEBI (LODR) Regulations, 2015

Dear Sir/ Madam,

Pursuant to Regulation 30 read with Schedule III to the Securities and Exchange Board of India (Listing Obligation and Disclosure Requirements) Regulation, 2015 (“Listing Regulations”) and pursuant to the Scrutinizer’s Report received from M/s. DSMR & Associates, Company Secretaries, dated 17 June 2025, we wish to inform you that the members of the Company have approved the following matters vide Postal Ballot which are deemed to have been passed on 16 June 2025:

1. To ratify ESOP Scheme 2008 of Sai Life Sciences Limited
2. Ratification of the extension of the benefits of ESOP Scheme 2008 to the employees of subsidiary companies and group companies of Sai Life Sciences Limited
3. To ratify Management ESOP Scheme 2018 of Sai Life Sciences Limited
4. Ratification of the extension of the benefits of Management ESOP Scheme 2018 to the employees of subsidiary companies and group companies of Sai Life Sciences Limited
5. Appointment of Dr. Dinesh V Patel (DIN-11010657) to the office of Independent Director
6. Appointment of Mr. Sivaramakrishnan Chittor (DIN-01092158) as Whole-Time Director of the Company

Further, the details required as per SEBI Circular SEBI/HO/CFD/PoD2/CIR/P/0155 dated 11 November 2024 are enclosed herewith.

We request you to take note of the same and oblige.

Thank you.

For **Sai Life Sciences Limited**

---

**Runa Karan**  
**Company Secretary & Compliance Officer**  
**Membership No.: A13721**

**Encl: As above**

**Sai Life Sciences Limited** (CIN: U24110TG1999PLC030970)

**Corporate office**

# L4-01 & 02, SLN Terminus, Survey  
#133, Gachibowli Miyapur Road,  
Gachibowli, Hyderabad – 500032,  
Telangana, India.

**Registered office**

Plot No. DS-7, IKP Knowledge Park, Turkapally  
(V), Shameerpet Mandal, Medchal-Malkajgiri  
(Dist), Hyderabad -500078, Telangana, India.

**Contact us**

T: +91 40 6815 6000,  
F: +91 40 6815 6199  
E: info@sailife.com  
W: www.sailife.com

**Annexure-A**

**Details required under Regulation 30 read with Schedule III of the Listing Regulations and as per SEBI Circular SEBI/HO/CFD/PoD2/CIR/P/0155 dated 11 November 2024.**

**ESOP Schemes**

<b>Sl. No.</b>	<b>Disclosures</b>	<b>Particulars – ESOP 2008</b>	<b>Particulars – Management ESOP 2018</b>
a)	<b>brief details of options granted</b>	The present instance is for ratification of ESOP 2008 (Pre-IPO Scheme) as per the requirements of Regulation 12 of SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021	The present instance is for ratification of Management ESOP 2018 (Pre-IPO Scheme) as per the requirements of Regulation 12 of SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021
b)	<b>Whether the scheme is in terms of SEBI (SBEB) Regulations, 2021 (if applicable)</b>	Yes	Yes
c)	<b>total number of shares covered by these options</b>	The maximum options under this scheme shall be 60,99,820 options. The aggregate number of equity shares set aside in relation to options which will be granted under this scheme shall correspond to 60,99,820 equity shares.	The maximum options under this scheme shall be 79,45,490 options. The aggregate number of equity shares set aside in relation to options which will be granted under this scheme shall correspond to 79,45,490 equity shares.
d)	<b>pricing formula</b>	The price payable by an Employee on Exercise is determined by the Nomination and Remuneration Committee and in conformity with applicable accounting Standards, the SEBI SBEB & SE Regulations as applicable from time to time.	The price payable by an Employee on Exercise is determined by the Nomination and Remuneration Committee and in conformity with applicable accounting Standards, the SEBI SBEB & SE Regulations as applicable from time to time.
e)	<b>options vested</b>	The number of vested and unexercised options as on date is 368500	The number of vested and unexercised options as on date is 1296490.
f)	<b>time within which option may be exercised</b>	Kindly refer to the explanatory statement for Item Nos. 1, 2, 3 and 4 of the <a href="#">Postal Ballot Notice</a> dated 15 May 2025.	Kindly refer to the explanatory statement for Item Nos. 1, 2, 3 and 4 of the <a href="#">Postal Ballot Notice</a> dated 15 May 2025.
g)	<b>options exercised</b>	The number of exercised options as on date is 6482180.	The number of exercised options as on date is 1223930.
h)	<b>money realized by exercise of options</b>	The current instance of disclosure is for ratification of Pre-IPO ESOP Scheme, hence not applicable.	The current instance of disclosure is for ratification of Pre-IPO ESOP Scheme, hence not applicable.
i)	<b>the total number of shares arising as a result of exercise of option</b>	The current instance of disclosure is for ratification of Pre-IPO ESOP Scheme, hence not applicable.	The current instance of disclosure is for ratification of Pre-IPO ESOP Scheme, hence not applicable.
j)	<b>options lapsed</b>	The current instance of disclosure is for ratification of Pre-IPO ESOP Scheme, hence not applicable.	The current instance of disclosure is for ratification of

**Sai Life Sciences Limited** (CIN: U24110TG1999PLC030970)

**Corporate office**

# L4-01 & 02, SLN Terminus, Survey #133, Gachibowli Miyapur Road, Gachibowli, Hyderabad – 500032, Telangana, India.

**Registered office**

Plot No. DS-7, IKP Knowledge Park, Turkapally (V), Shameerpet Mandal, Medchal-Malkajgiri (Dist), Hyderabad -500078, Telangana, India.

**Contact us**

T: +91 40 6815 6000,  
F: +91 40 6815 6199  
E: info@sailife.com  
W: www.sailife.com



# Sai

Make it  
better  
together

			Pre-IPO ESOP Scheme, hence not applicable.
k)	variation of terms of options	NA	NA
l)	brief details of significant terms	Kindly refer to the explanatory statement for Item Nos. 1, 2, 3 and 4 of the <a href="#">Postal Ballot Notice</a> dated 15 May 2025.	Kindly refer to the explanatory statement for Item Nos. 1, 2, 3 and 4 of the <a href="#">Postal Ballot Notice</a> dated 15 May 2025.
m)	subsequent changes or cancellation or exercise of such options	NA	NA
n)	diluted earnings per share pursuant to issue of equity shares on exercise of options	NA	NA

**Sai Life Sciences Limited** (CIN: U24110TG1999PLC030970)

**Corporate office**

# L4-01 & 02, SLN Terminus, Survey  
#133, Gachibowli Miyapur Road,  
Gachibowli, Hyderabad – 500032,  
Telangana, India.

**Registered office**

Plot No. DS-7, IKP Knowledge Park, Turkapally  
(V), Shameerpet Mandal, Medchal-Malkajgiri  
(Dist), Hyderabad -500078, Telangana, India.

**Contact us**

T: +91 40 6815 6000,  
F: +91 40 6815 6199  
E: [info@sailife.com](mailto:info@sailife.com)  
W: [www.sailife.com](http://www.sailife.com)

**Annexure-B**

**The details as required in terms of Regulation 30 read with of Schedule III of the LODR and SEBI Master Circular dated 11 November 2024**

**Appointment of Dr. Dinesh V Patel (DIN-11010657) to the office of Independent Director**

<b>S. No</b>	<b>Particulars</b>	<b>Description</b>
1	Reason for change viz. <del>appointment, re-appointment, resignation, removal, death or otherwise</del>	Dr. Dinesh V Patel (DIN: 11010657) was appointed as an Additional Director of the Company under the category of Independent Director by the Board of Directors on 24 March 2025, subject to the approval of members.  The members of the Company have approved his appointment vide Postal Ballot dated 16 June 2025.
2	Date of appointment/ <del>re-appointment/cessation</del> & term of appointment/ <del>re-appointment</del>	The original date of appointment by the Board of Directors is 24 March 2025 which has been approved by the members vide Postal Ballot.  The first term of five consecutive years has commenced from 24 March 2025 and will end on 23 March 2030
3	Brief Profile (In case of Appointment)	Dr. Patel has served as a member of the board of directors and as the President and Chief Executive Officer of Protagonist Therapeutics since December 2008. He has 38 years of executive, entrepreneurial, and scientific experience that span the pharmaceutical, biotechnology and biopharmaceutical industries. Prior to joining Protagonist, Dr. Patel served from 2006 to 2008 as the President and Chief Executive Officer of Arête Therapeutics, a privately held company focused on novel drugs for metabolic syndrome. Previously, he was the Chief Executive Officer and Co-founder of Miikana Therapeutics, an oncology based company, from 2003 until acquired by Entremed (later renamed CASI Pharmaceuticals) in 2005. Prior to Miikana, Dr. Patel held positions of increasing responsibility at Versicor (later renamed Vicuron) from 1996 to 2003, most recently as Senior Vice President of Drug Discovery and Licensing. Vicuron research and development efforts led to two marketed drugs, anidulafungin (Eraxis®), and Dalbavancin (Dalvance®), and the Company was acquired by Pfizer in 2005 in a \$1.9 billion cash transaction. From 1993 to 1996, Dr. Patel was a director of chemistry at the combinatorial chemistry company Affymax. Dr. Patel was a medicinal chemist at Bristol-Myers Squibb from 1985 to 1993. He

**Sai Life Sciences Limited** (CIN: U24110TG1999PLC030970)

**Corporate office**

# L4-01 & 02, SLN Terminus, Survey #133, Gachibowli Miyapur Road, Gachibowli, Hyderabad – 500032, Telangana, India.

**Registered office**

Plot No. DS-7, IKP Knowledge Park, Turkapally (V), Shameerpet Mandal, Medchal-Malkajgiri (Dist), Hyderabad -500078, Telangana, India.

**Contact us**

T: +91 40 6815 6000,  
F: +91 40 6815 6199  
E: info@sailife.com  
W: www.sailife.com

		received his Ph.D. in Chemistry from Rutgers University, New Jersey and his M.Sc. and B.Sc. in Chemistry from S. P. University, Vallabh Vidyanagar, India.
4	Disclosure of relationships between directors (in case of appointment of director)	Dr. Dinesh V Patel is not related to any of the Promoters, Directors or Key Managerial Personnel of the Company.
5	Information as required pursuant to BSE Circular no. LIST/COMP/14/2018-19 and NSE Circular No. NSE/CMU2018/24 dated 20 June 2018	Dr. Dinesh V Patel is not debarred from holding office of a director by virtue of any order passed by the Securities and Exchange Board of India or any other such authority.

**Sai Life Sciences Limited** (CIN: U24110TG1999PLC030970)

**Corporate office**

# L4-01 & 02, SLN Terminus, Survey  
#133, Gachibowli Miyapur Road,  
Gachibowli, Hyderabad – 500032,  
Telangana, India.

**Registered office**

Plot No. DS-7, IKP Knowledge Park, Turkapally  
(V), Shameerpet Mandal, Medchal-Malkajgiri  
(Dist), Hyderabad -500078, Telangana, India.

**Contact us**

T: +91 40 6815 6000,  
F: +91 40 6815 6199  
E: info@sailife.com  
W: www.sailife.com

**Annexure-C**

**The details as required in terms of Regulation 30 read with of Schedule III of the LODR and SEBI Master Circular dated 11 November 2024**

**Appointment of Mr. Sivaramakrishnan Chittor (DIN-01092158) as Whole-Time Director of the Company**

<b>S. No</b>	<b>Particulars</b>	<b>Description</b>
1	Reason for change viz. appointment, <del>re-appointment, resignation, removal, death or otherwise</del>	Mr. Sivaramakrishnan Chittor, (DIN: 01092158) was appointed as an Additional Director of the Company on 28 April 2025 by the Board of Directors in addition to his current designation of Chief Financial Officer (“CFO”) in the Company.  Pursuant to the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, the members of the Company vide Postal Ballot dated 16 June 2025, have approved appointment of Mr. Sivaramakrishnan Chittor as Whole Time Director & Chief Financial Officer for a period of 5 years from the date of such approval.
2	Date of appointment/ <del>re-appointment/cessation</del> & term of appointment/ <del>re-appointment</del>	The date of fresh appointment as a Whole Time Director is the date of such approval by the members i.e., 16 June 2025.  Term of Appointment – 5 years from the effective date of appointment.
3	Brief Profile (In case of Appointment)	Sivaramakrishnan Chittor is the Chief Financial Officer of our Company. He joined our Company on January 21, 2009 as the senior vice president & head of finance. He is responsible for strategic planning, operational oversight and financial management of our Company. He is a member of the Institute of Chartered Accountants of India. He has passed the final examination held by the Institute of Company Secretaries of India. He was previously associated with CGI Information Systems & Management Consultants, Inc. (formerly known as IMRglobal Corporation) as its administrative director and controller. He was last associated with Zavata as its senior vice president – shared services.
4	Disclosure of relationships between directors (in case of appointment of director)	Mr. Sivaramakrishnan Chittor is not related to any of the Promoters, Directors or Key Managerial Personnel of the Company.  However, please note that the appointment of Mr. Sivaramakrishnan Chittor as a Whole Time Director of the Company is in addition to his current designation of CFO.
5	Information as required pursuant to BSE Circular no. LIST/COMP/14/2018-19 and NSE Circular No. NSE/CMU2018/24 dated 20 June 2018	Mr. Sivaramakrishnan Chittor is not debarred from holding office of a director by virtue of any order passed by the Securities and Exchange Board of India or any other such authority.

**Sai Life Sciences Limited** (CIN: U24110TG1999PLC030970)

**Corporate office**

# L4-01 & 02, SLN Terminus, Survey #133, Gachibowli Miyapur Road, Gachibowli, Hyderabad – 500032, Telangana, India.

**Registered office**

Plot No. DS-7, IKP Knowledge Park, Turkapally (V), Shameerpet Mandal, Medchal-Malkajgiri (Dist), Hyderabad -500078, Telangana, India.

**Contact us**

T: +91 40 6815 6000,  
F: +91 40 6815 6199  
E: info@sailife.com  
W: www.sailife.com